Strategic Partnerships
Strategic partnerships advance our efforts to pioneer new research, deliver new treatments and advance patient care.
Partnering with Acadia
We can’t create life-changing medicines alone. We actively seek partnerships and collaborations that drive therapeutic advancements for patients and families forward.
Successfully developing the first FDA-approved treatment for hallucinations and delusions associated with Parkinson’s disease psychosis is a testament to our commitment to partnerships through all stages of clinical and commercial life cycle.
Finding the Right Partnerships
When considering partners, we focus on a range of criteria to ensure each collaboration is the right fit.
- Evaluation: Our evaluation process includes a focus on differentiated science and novel product candidates in areas with significant unmet need.
- Focus Areas: Our ideal partnerships are within our strategic focus areas of CNS disorders (neurology and psychiatry) and genetic diseases.
- Phase: We are interested in opportunities from pre-clinical through Phase 3 programs to commercial-stage products.
Our Current Partnerships
Our partnerships are an important part of our mission to trailblaze innovative neuroscience solutions.
Neuren Pharmaceuticals
Acadia holds an exclusive Global License Agreement with Neuren Pharmaceuticals for the development and commercialization of trofinetide for Rett syndrome and other indications. Additionally, Acadia holds exclusive worldwide rights to NNZ-2591 in both Rett syndrome and Fragile X syndrome. NNZ-2591 is currently under development by Neuren in four other rare neurodevelopmental syndromes.
Stoke Therapeutics
Acadia and Stoke Therapeutics have a collaboration to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The collaboration includes a discovery program for SYNGAP1 syndrome.
Saniona
Acadia and Saniona have a license agreement for the development and commercialization of ACP-711, a highly selective GABAA-α3 positive allosteric modulator. The first indication Acadia is pursuing is essential tremor, a neurological condition that includes shaking or trembling movements in one or more parts of the body.
Partner with Us
We welcome the opportunity to learn how we can work together. To further explore partnering opportunities, please contact us.